Immunogenicity, safety and tolerability of intradermal influenza vaccines

Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial

(2016) Ivan Fan-Ngai Hung et al.   LANCET INFECTIOUS DISEASES

A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly

(2016) Yotam Levin et al.   VACCINE

Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview

(2016) Nicola Luigi Bragazzi et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of intradermal influenza vaccine in immunocompromized patients: a meta-analysis of randomized controlled trials

(2015) Claudia Pileggi et al.   BMC INFECTIOUS DISEASES

Immunogenicity and Safety of Intradermal Influenza Vaccine in the Elderly: A Meta-Analysis of Randomized Controlled Trials

(2015) Claudia Pileggi et al.   DRUGS & AGING

Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers

(2015) Brenda L. Coleman et al.   VACCINE

Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future

(2015) Yotam Levin et al.   Human Vaccines & Immunotherapeutics

Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review

(2015) Barbara Camilloni et al.   Human Vaccines & Immunotherapeutics

Toll-Like Receptor 7 Agonist Imiquimod in Combination with Influenza Vaccine Expedites and Augments Humoral Immune Responses against Influenza A(H1N1)pdm09 Virus Infection in BALB/c Mice

(2014) Anna J. X. Zhang et al.   Clinical and Vaccine Immunology

Immunogenicity of Intradermal Trivalent Influenza Vaccine With Topical Imiquimod: A Double Blind Randomized Controlled Trial

(2014) Ivan F. N. Hung et al.   CLINICAL INFECTIOUS DISEASES

Response to Comments on “Immunogenicity and Safety of Intradermal Trivalent Influenza Vaccination in Nursing Home Older Adults: A Randomized Controlled Trial”

(2014) Tuen-Ching Chan et al.   Journal of the American Medical Directors Association

A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration

(2014) Giovanni Della Cioppa et al.   Human Vaccines & Immunotherapeutics

Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains

(2014) Barbara Camilloni et al.   Immunity & Ageing

Intanza®9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age

(2013) Isabel Leroux-Roels et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of Intanza®/IDflu®intradermal influenza vaccine in South Korean adults: A multicenter, randomized trial

(2013) Sang Hoon Han et al.   Human Vaccines & Immunotherapeutics

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60

(2013) Filippo Ansaldi et al.   Human Vaccines & Immunotherapeutics

Acceptance and Opinions of Intanza/IDflu Intradermal Influenza Vaccine in the Czech Republic and Turkey

(2012) Roman Prymula et al.   ADVANCES IN THERAPY

Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010–2011 influenza season

(2012) Patrick A. Dhont et al.   ADVANCES IN THERAPY

A Meta-analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events

(2012) Fawziah Marra et al.   Influenza and Other Respiratory Viruses

Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain

(2012) Ivan F.N. Hung et al.   VACCINE

Intanza® 15mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses

(2012) Filippo Ansaldi et al.   VACCINE

Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany

(2011) Robert Arnou et al.   ADVANCES IN THERAPY

Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina

(2011) Peter Eizenberg et al.   ADVANCES IN THERAPY

Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement

(2011) Filippo Ansaldi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A systematic review of intradermal influenza vaccines

(2011) Flora Young et al.   VACCINE

Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination

(2011) Ivan F.N. Hung et al.   VACCINE

Intanza®: a new intradermal vaccine for seasonal influenza

(2010) Robert L Atmar et al.   Expert Review of Vaccines

Fractional Doses of Inactivated Poliovirus Vaccine in Oman

(2010) Ali Jafer Mohammed et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells

(2009) Xian-Zhen Chen et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Virosomal Hepatitis A Vaccine: Comparing Intradermal and Subcutaneous With Intramuscular Administration

(2009) Gert Frösner et al.   JOURNAL OF TRAVEL MEDICINE

Intradermal hepatitis B vaccination: A systematic review and meta-analysis

(2009) Laura Sangaré et al.   VACCINE

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults

(2008) Pierre Van Damme et al.   VACCINE